ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III Estrogen Receptor positive HER2 negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106
- Citation:
- J Clin Oncol vol 38 (15_suppl) 504
- Meeting Instance:
- ASCO 2020
- Year:
- 2020
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3910
- Pharmas:
- AstraZeneca, Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171, U10CA180868 (NRG); Alliance Foundation
- Corr. Author:
- Authors:
- Cynthia X. Ma Vera Suman A. Marilyn Leitch Souzan Sanati Kiran Vij Gary W. Unzeitig Jeremy Hoog Mark Watson Olwen Hahn Joseph Guenther Abigail Caudle J. Michael Guenther Travis Dockter Larissa Korde Anna Weiss Kelly Hunt Clifford Hudis Eric P. Winer Ann Partridge Lisa Carey Matthew J. Ellis
- Networks:
- KY015, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC007, LAPS-NY016, LAPS-TX011, LAPS-TX035, NY167, TX041, TX190
- Study
- Alliance-A011106
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: